Shares of VIVUS Inc. (NASDAQ: VVUS) continued yesterday’s ascent in early trading, up 1.11% to $11.82 shortly after the opening bell. VVUS closed 9.56% higher at $11.69, with volume up from daily average of 4.67 million to 12.78 million. The stock was active again in after-hours trading today. It fell 0.77% to $11.60 in after-hours trading.
VIVUS has a 52-week range of $5.55-$13.68. It is currently trading above its 50-day and 200-day moving averages of $11.19 and $9.57, respectively. The stock has seen support at $9.76. It has broken through its resistance level of $11.41 in Thursday’s trading.
Wedbush recently initiated coverage on the VIVUS with an Outperform rating. Wedbush has set a price target of $20 on the VIVUS stock. The stock has a consensus recommendation of Outperform. Currently, it has 1 Buy, 5 Outperform and 6 Hold ratings.
VIVUS is likely to be in the news over the next few days as its drug candidate for obesity, Qnexa, will come up for review with the U.S. FDA on July 15. If Qnexa is approved by the U.S. FDA, it will be the first prescription drug for the treatment of obesity in a decade in the U.S.
Going by the past history of drugs for treatment of obesity that have come up for review by the FDA, the future for FDA approval is questinable. According to Reuters report, in the past, pills for obesity have not been approved by the FDA, or have received severe warnings, or have been taken off the market.
Apart from Qnexa, VIVUS’ other drug candidate, Avanafil, is in phase 3 trials for erectile dysfunction.
About BeaconEquity.com
BeaconEquity.com is committed to producing the highest-quality insight and analysis of small cap stocks, emerging technology stocks, hot penny stocks and helping investors make informed decisions. Our focus is primarily on the underserved OTC stocks market, or “penny stock” market, which has traditionally been shunned by Wall Street. We have particular expertise with renewable energy stocks, biotech stocks, oil stocks, green energy stocks and internet stocks. There are many hot penny stock opportunities present in the OTC market everyday and we seek to exploit these hot stock gains for our members before the average daytrader is aware of them.
- Need fast service and cheap rates from a broker? Buy stock online at my favorite brokerage
- See today’s top stock picks and market analysis
- Want more? Check out the message board buzz for these stocks
- See what newsletters are recommending these stock picks
- Get breaking news alerts on these stocks: http://thestockmarketwatch.com/
- This newsletter has been helping traders make a killing on these stocks. Click here for a 25% discount offer.
About BeaconEquity.com
BeaconEquity.com is committed to producing the highest-quality insight and analysis of small-cap stocks, emerging technology stocks, hot penny stocks and helping investors make informed decisions. Our focus is primarily OTC stocks in the stock market today, which have traditionally been shunned by Wall Street. We have particular expertise with renewable energy stocks, biotech stocks, oil stocks, green energy stocks and internet stocks. There are many hot penny stock opportunities present in the OTC market everyday and we seek to exploit these hot stock gains for our members before the average daytrader is aware of them.
Beacon Equity Group Disclaimer
This newsletter is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Beaconequity.com is a wholly-owned subsidiary of BlueWave Advisors.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
